Sustained Response of Ibrutinib in a Patient with Waldenstrom Macroglobulinemia Presenting with Myasthenic Crisis as a Paraneoplastic Neurological Syndrome: A Case Report and Review of Literature
Keywords:
paraneoplastic, myasthenia gravis, ibrutinib, waldenstrom macroglobulinemiaAbstract
Paraneoplastic syndrome is a broad spectrum of signs and symptoms due to neoplasm, attributed to substances produced by tumor cells, or in response to it. Myasthenia gravis (MG) is a well-known paraneoplastic neurological syndrome (PNS), frequently associated with thymic abnormalities, but rarely reported in patients with lymphoplasmacytic lymphoma.This study presents the case of a 52-year-old Indonesian male patient who was diagnosed with Waldenstrom macroglobulinemia (WM), a rare B-cell neoplasm, after developing a new onset of MG with myasthenic crisis. the patient’s MG features improved with Ibrutinib as a treatment targeted toward cancer. This is the first case report presenting the treatment response of Ibrutinib in WM with myasthenic crisis. The literature was reviewed to explain the possibility of MG as a paraneoplastic syndrome of WM and the treatment response of Ibrutinib for this patient, as well as summarizing previous case reports of concomitant MG and WM.MG should be considered a paraneoplastic malignancy syndrome, including WM, during diagnostic workup. Ibrutinib should also be considered when available to patients, due to its adequate response in both previously treated and treatment naïve patients.References
Rivner MH, Pasnoor M, Dimachkie M, et al. MuSK and Myasthenia Gravis due to other Antibodies. Neurol Clin. 2018;36:293–310.
Ravi G, Kapoor P. Current approach to Waldenström macroglobulinemia. Cancer Treat Res Commun. 2022;31:100527.
World Health Organization. WHO classification of tumors of hematopoietic and lymphoid tissues. Revised 4th edition. In: Swerdlow SH, Campo E, Harris NL, et al., editors. Lyon: International Agency for Research on Cancer; 2017. p. 585. (World Health Organization classification of tumors).
Pelosof LC, Gerber DE. Paraneoplastic syndromes: An approach to diagnosis and treatment. Mayo Clin Proc. 2010;85:838–54.
Leypoldt F, Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol. 2014;175:336–48.
Bartoloni C, Scoppetta C, Flamini G, et al. Waldenström’s macroglobulinemia and myasthenia gravis. J Clin Lab Immunol. 1981;6:275–8.
Lin YT, Kuo HC, Chang YT, et al. Myasthenia gravis and Waldenström’s macroglobulinemia: a case report and review of the literature. Acta Neurol Scand. 2001;104:246–8.
Valles-Antuña C, Lozano B, Mozo L, et al. P949: Musk-antibody-positive myasthenia gravis in association with Waldenstrom’s macroglobulinemia. A case report. Clin Neurophysiol. 2014;125:S135–6.
Malkan UY, Gunes G, Eliacik E, et al. Myasthenia gravis and Waldenstrom macroglobulinemia: is common immunologic mechanism possible? Leuk Res. 2014;38:S46.
Rezania K, Soliven B, Baron J, et al. Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of literature. Leuk Lymphoma. 2012;53:371–80.
Papanota AM, Ntanasis-Stathopoulos I, Kastritis E, et al. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia. J Blood Med. 2019;10:291–300.
Sermer D, Sarosiek S, Branagan AR, et al. Targeted Therapies and Emerging Novel Treatment Approaches for Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk [Internet]. 2022 [cited 2022 Mar 29]; Available from: https://www.sciencedirect.com/science/article/pii/S2152265022000635
Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia. N Engl J Med. 2015;372:1430–40.
Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017;18:241–50.
Treon SP, Gustine J, Meid K, et al. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:2755–61.
Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström’s Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:52–62.
Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015;126:721–32.
Downloads
Published
How to Cite
Issue
Section
License
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
